Patents by Inventor Nicole D. Zantek

Nicole D. Zantek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EPHA2 as a therapeutic target for cancer
    Patent number: 8591887
    Abstract: The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: November 26, 2013
    Assignee: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek, Patrick W. Hein
  • ANTIBODIES AS A CANCER DIAGNOSTIC
    Publication number: 20120122112
    Abstract: Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.
    Type: Application
    Filed: August 16, 2011
    Publication date: May 17, 2012
    Applicant: Purdue Research Foundation
    Inventors: Michael S. KINCH, Nicole D. Zantek
  • EPHA2 as a therapeutic target for cancer
    Publication number: 20110150898
    Abstract: The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
    Type: Application
    Filed: January 7, 2010
    Publication date: June 23, 2011
    Applicant: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek, Patrick W. Hein
  • EphA2 as a therapeutic target for cancer
    Patent number: 7776327
    Abstract: The present invention is directed to compounds and methods for the treatment of cancer. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic cancer.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: August 17, 2010
    Assignee: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek, Patrick W. Hein
  • EphA2 as a diagnostic target for metastatic cancer
    Patent number: 7192698
    Abstract: Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: March 20, 2007
    Assignee: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek
  • Treatment of metastatic disease
    Patent number: 6927203
    Abstract: The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: August 9, 2005
    Assignee: Purdue Research Foundation
    Inventors: Michael S. Kinch, Nicole D. Zantek, Patrick W. Hein